(Q30396654)

21 June 2017

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine (English)

1 reference

21 June 2017

0 references

1 reference

2

Saul N Faust

1 reference

21 June 2017

Woolf T Walker

1

1 reference

21 June 2017

1 December 2010

1 reference

Expert Review of Vaccines

21 June 2017

1 reference

21 June 2017

9

1 reference

21 June 2017

12

1 reference

21 June 2017

1385-1398

1 reference

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

21 June 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Mitigation strategies for pandemic influenza in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Influenza pandemics of the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Influenza A: From highly pathogenic H5N1 to pandemic 2009 H1N1. Epidemiology and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Australia's winter with the 2009 pandemic influenza A (H1N1) virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Squalene, olive oil, and cancer risk. Review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Re: Antibodies to squalene in Gulf War Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Vaccination, squalene and anti-squalene antibodies: facts or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Thimerosal and Vaccines — A Cautionary Tale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

The toxicology of mercury and its chemical compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Recommendations for the administration of influenza vaccine in children allergic to egg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Risk of Anaphylaxis After Vaccination of Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

H1N1 2009 influenza virus infection during pregnancy in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Effectiveness of maternal influenza immunization in mothers and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Vaccines and Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

Large trials confirm immunogenicity of H1N1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.141

21 January 2018

Identifiers

DOI

10.1586/ERV.10.141

1 reference

21 June 2017

1 reference

PubMed ID

21105775